diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine

This drug is a combination vaccine (DTaP-IPV or dTaP-IPV) designed to provide active immunization against four major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. It contains **diphtheria toxoid**, **tetanus toxoid**, **acellular pertussis (aP)** antigens (typically including pertussis toxin, filamentous hemagglutinin, and pertactin), and **inactivated poliovirus (IPV)** types 1, 2, and 3. The vaccine works by inducing the production of specific antibodies and memory cells against the toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani*, the surface antigens of *Bordetella pertussis*, and the three types of poliovirus. In the context of the **KIM-study** conducted by **Stichting Radboud University Medical Center** in the Netherlands, a licensed dTaP-IPV booster is being evaluated in a controlled human infection model (CHIM) to investigate how acellular pertussis vaccination affects the colonization of *Bordetella pertussis* in healthy adult volunteers. Major commercial versions of this combination include **Boostrix-IPV** (developed by GSK) and **Repevax** (developed by Sanofi).

Brand names

Boostrix-IPVRepevaxAdacel-PolioKinrixQuadracel

Other names

DTaP-IPVTdap-IPVacellular pertussis vaccine with diphtheria + tetanus + inactivated poliovirus antigens